96 related articles for article (PubMed ID: 38500204)
1. A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo.
Michael C; Mendonça-Gomes JM; DePaolo CW; Di Cristofano A; de Oliveira S
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38657656
[TBL] [Abstract][Full Text] [Related]
2. Characterization of EpCAM in thyroid cancer biology by three-dimensional spheroids in vitro model.
Ghiandai V; Grassi ES; Gazzano G; Fugazzola L; Persani L
Cancer Cell Int; 2024 Jun; 24(1):196. PubMed ID: 38835027
[TBL] [Abstract][Full Text] [Related]
3. Wnt/β-catenin signaling is a therapeutic target in anaplastic thyroid carcinoma.
Diaz D; Bergdorf K; Loberg MA; Phifer CJ; Xu GJ; Sheng Q; Chen SC; Byrant JM; Tigue ML; Hartmann H; Rohde SL; Netterville JL; Baregamian N; Goettel JA; Ye F; Lee E; Weiss VL
Endocrine; 2024 May; ():. PubMed ID: 38806891
[TBL] [Abstract][Full Text] [Related]
4. Primary Squamous Cell Carcinoma of the Thyroid Has a Molecular Genetic Profile Distinct From That of Anaplastic Thyroid Carcinoma: A Whole Exome Sequencing and Gene Expression Profiling Study.
Ye M; Guo Z; Xu J; Jin Y; He X; Ge M
Am J Surg Pathol; 2024 May; ():. PubMed ID: 38775423
[TBL] [Abstract][Full Text] [Related]
5. Advances in the management of anaplastic thyroid carcinoma: transforming a life-threatening condition into a potentially treatable disease.
Califano I; Smulever A; Jerkovich F; Pitoia F
Rev Endocr Metab Disord; 2024 Feb; 25(1):123-147. PubMed ID: 37648897
[TBL] [Abstract][Full Text] [Related]
6. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
[TBL] [Abstract][Full Text] [Related]
7. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract][Full Text] [Related]
8. Combination
Gunda V; Ghosh C; Hu J; Zhang L; Zhang YQ; Shen M; Kebebew E
Thyroid; 2023 Oct; 33(10):1201-1214. PubMed ID: 37675898
[No Abstract] [Full Text] [Related]
9. Histological features of BRAF V600E-mutant anaplastic thyroid carcinoma.
Chen TY; Lorch JH; Wong KS; Barletta JA
Histopathology; 2020 Aug; 77(2):314-320. PubMed ID: 32428249
[TBL] [Abstract][Full Text] [Related]
10. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation.
Fallahi P; Ferrari SM; La Motta C; Materazzi G; Bocci G; Da Settimo F; Miccoli P; Antonelli A
Endocrine; 2016 Jul; 53(1):136-44. PubMed ID: 26286966
[TBL] [Abstract][Full Text] [Related]
11. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
12. The next generation of orthotopic thyroid cancer models: immunocompetent orthotopic mouse models of BRAF V600E-positive papillary and anaplastic thyroid carcinoma.
Vanden Borre P; McFadden DG; Gunda V; Sadow PM; Varmeh S; Bernasconi M; Jacks T; Parangi S
Thyroid; 2014 Apr; 24(4):705-14. PubMed ID: 24295207
[TBL] [Abstract][Full Text] [Related]
13. Utilizing CD44v6 and V600EBRAF-mutation for in vitro targeted combination therapy of thyroid carcinomas.
Mortensen ACL; Imgenberg-Kreuz J; Spiegelberg D; Botling J; Nestor M
Heliyon; 2023 Dec; 9(12):e22594. PubMed ID: 38076095
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis between 2D and 3D colorectal cancer culture models for insights into cellular morphological and transcriptomic variations.
Abbas ZN; Al-Saffar AZ; Jasim SM; Sulaiman GM
Sci Rep; 2023 Oct; 13(1):18380. PubMed ID: 37884554
[TBL] [Abstract][Full Text] [Related]
15. Transcriptional Landscape of 3D vs. 2D Ovarian Cancer Cell Models.
Kerslake R; Belay B; Panfilov S; Hall M; Kyrou I; Randeva HS; Hyttinen J; Karteris E; Sisu C
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444459
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
